Home • Projects • Galvus (vildagliptin) - DPP-IV Inhibitor / Oral

Current estimates indicate that worldwide about 170 million people suffer from diabetes, which is projected to reach 366 million by 2030.

«Back

---

Home | New On This Site | Products & Services | Company A-Z | Industry Projects | White Papers | Jobs & Careers | Press Releases | Events & Exhibitions | Newsletter | Organisations | About Us | Contact Us | Advertise With Us |